These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 29216999)
1. Characteristics, Predictors, and Mechanisms of Thrombosis in Coronary Bioresorbable Scaffolds: Differences Between Early and Late Events. Gori T; Weissner M; Gönner S; Wendling F; Ullrich H; Ellis S; Anadol R; Polimeni A; Münzel T JACC Cardiovasc Interv; 2017 Dec; 10(23):2363-2371. PubMed ID: 29216999 [TBL] [Abstract][Full Text] [Related]
2. Incidence, Clinical Presentation, and Predictors of Clinical Restenosis in Coronary Bioresorbable Scaffolds. Polimeni A; Weissner M; Schochlow K; Ullrich H; Indolfi C; Dijkstra J; Anadol R; Münzel T; Gori T JACC Cardiovasc Interv; 2017 Sep; 10(18):1819-1827. PubMed ID: 28935073 [TBL] [Abstract][Full Text] [Related]
3. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries. Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648 [TBL] [Abstract][Full Text] [Related]
4. Outcome of percutaneous coronary intervention with the Absorb bioresorbable scaffold: data from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Grimfjärd P; James S; Persson J; Angerås O; Koul S; Omerovic E; Varenhorst C; Lagerqvist B; Erlinge D EuroIntervention; 2017 Dec; 13(11):1303-1310. PubMed ID: 28781242 [TBL] [Abstract][Full Text] [Related]
5. Bioresorbable Coronary Scaffold Thrombosis: Multicenter Comprehensive Analysis of Clinical Presentation, Mechanisms, and Predictors. Puricel S; Cuculi F; Weissner M; Schmermund A; Jamshidi P; Nyffenegger T; Binder H; Eggebrecht H; Münzel T; Cook S; Gori T J Am Coll Cardiol; 2016 Mar; 67(8):921-931. PubMed ID: 26916481 [TBL] [Abstract][Full Text] [Related]
6. Predictors of bioresorbable scaffold failure in STEMI patients at 3 years follow-up. Polimeni A; Anadol R; Münzel T; De Rosa S; Indolfi C; Gori T Int J Cardiol; 2018 Oct; 268():68-74. PubMed ID: 30041805 [TBL] [Abstract][Full Text] [Related]
7. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction). Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924 [TBL] [Abstract][Full Text] [Related]
8. Procedural and Long-Term Outcomes of Bioresorbable Scaffolds Versus Drug-Eluting Stents in Chronic Total Occlusions: The BONITO Registry (Bioresorbable Scaffolds Versus Drug-Eluting Stents in Chronic Total Occlusions). Azzalini L; Giustino G; Ojeda S; Serra A; La Manna A; Ly HQ; Bellini B; Benincasa S; Chavarría J; Gheorghe LL; Longo G; Miccichè E; D'Agosta G; Picard F; Pan M; Tamburino C; Latib A; Carlino M; Chieffo A; Colombo A Circ Cardiovasc Interv; 2016 Oct; 9(10):. PubMed ID: 27765802 [TBL] [Abstract][Full Text] [Related]
9. Long-Term Clinical Outcomes of Patients Treated With Everolimus-Eluting Bioresorbable Stents in Routine Practice: 2-Year Results of the ISAR-ABSORB Registry. Wiebe J; Hoppmann P; Colleran R; Kufner S; Valeskini M; Cassese S; Schneider S; Joner M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA JACC Cardiovasc Interv; 2017 Jun; 10(12):1222-1229. PubMed ID: 28641842 [TBL] [Abstract][Full Text] [Related]
10. Three-years outcomes of diabetic patients treated with coronary bioresorbable scaffolds. Anadol R; Schnitzler K; Lorenz L; Weissner M; Ullrich H; Polimeni A; Münzel T; Gori T BMC Cardiovasc Disord; 2018 May; 18(1):92. PubMed ID: 29743023 [TBL] [Abstract][Full Text] [Related]
11. Everolimus-eluting bioresorbable scaffold implantation for the treatment of bifurcation lesions - Implications from early clinical experience during daily practice. Wiebe J; Dörr O; Bauer T; Liebetrau C; Boeder N; Möllmann H; Hamm CW; Nef HM Cardiovasc Revasc Med; 2016; 17(5):313-7. PubMed ID: 27085220 [TBL] [Abstract][Full Text] [Related]
12. Mid- to Long-Term Clinical Outcomes of Patients Treated With the Everolimus-Eluting Bioresorbable Vascular Scaffold: The BVS Expand Registry. Felix CM; Fam JM; Diletti R; Ishibashi Y; Karanasos A; Everaert BR; van Mieghem NM; Daemen J; de Jaegere PP; Zijlstra F; Regar ES; Onuma Y; van Geuns RJ JACC Cardiovasc Interv; 2016 Aug; 9(16):1652-63. PubMed ID: 27476094 [TBL] [Abstract][Full Text] [Related]